Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07224826, AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Next Previous
X
Search
Trial Profile

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07224826, AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary) ; PF 07224826 (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Liposarcoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 31 Jul 2023 Planned End Date changed from 14 Oct 2027 to 13 Apr 2028.
    • 31 Jul 2023 Planned primary completion date changed from 14 Oct 2025 to 14 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top